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Purpose: Repeating endoscopic retrograde cholangiopancreatography (ERCP) in patients with recurrent common bile 
duct (CBD) stones is problematic in many ways. Choledochoduodenostomy (CDS) and choledochojejunostomy (CJS) are 2 
surgical treatment options for recurrent CBD stones, and each has different advantages and disadvantages. The aim of this 
study was to compare the 2 surgical options in terms of the recurrence rate of CBD stones after surgical treatment.
Methods: This retrospective multicenter study included all patients who underwent surgical treatment due to recurrent 
CBD stones that were not effectively controlled by medical treatment and repeated ERCP between January 2006 and 
March 2015. We collected data from chart reviews and medical records. A recurrent CBD stone was defined as a stone 
found 6 months after the complete removal of a CBD stone by ERCP. Patients who underwent surgery for other reasons 
were excluded. 
Results: A total of 27 patients were enrolled in this study. Six patients underwent CDS, and 21 patients underwent CJS for 
the rescue treatment of recurrent CBD stones. The median follow-up duration was 290 (180–1,975) days in the CDS group 
and 1,474 (180–6,560) days in the CJS group (P = 0.065). The postoperative complications were similar and tolerable in both 
groups (intestinal obstruction; 2 of 27, 7.4%; 1 in each group). CBD stones recurred in 4 patients after CDS (4 of 6, 66.7%), 
and 3 patients after CJS (3 of 21, 14.3%) (P = 0.010). 
Conclusion: CJS may be a better surgical option than CDS for preventing further stone recurrence in patients with 
recurrent CBD stones. 
[Ann Surg Treat Res 2020;99(6):329-336]
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INTRODUCTION
Common bile duct (CBD) stones are a major cause of acute 
cholangitis, and endoscopic stone removal using endoscopic 
retrograde cholangiopancreatography (ERCP) is widely used 
as the primary treatment option. A CBD stone found within 6 
months after endoscopic stone removal is defined as a residual 
stone, and a CBD stone found after 6 months is defined as a 
recurrent stone. Recurrence within 6 months is not defined as a 
true CBD stone recurrence because it means that the CBD stone 
was not completely removed and remained after the previous 
attempt [1]. The recurrence of CBD stones after endoscopic 
biliary sphincterotomy has been reported in 4%–24% of the 
cases [2-7]. 
Because CBD stone recurrence can eventually lead to serious 
complications, such as recurrent cholangitis, hepatic abscess, 
biliary sepsis, and biliary cirrhosis, preventive methods are 
necessary for minimizing incomplete stone removal and stone 
recurrence. Therefore, to prevent CBD stone recurrence, it is 
important to identify and manage risk factors for CBD stones 
or diagnose and treat recurrent CBD stones early by regularly 
examining patients at high risk of recurrence.
Recurrent CBD stones are mostly pigmented gallstones that 
can be effectively and safely treated through ERCP procedures 
[8-11]. It is not known whether ursodeoxycholic acid (UDCA) 
is effective in preventing stone recurrence after successful 
removal. This is because data on the role of drug therapy after 
CBD stone removal are very limited, and the mechanism of 
pigmented stone formation, which accounts for the majority 
of recurrent CBD stones, is different from that of cholesterol 
gallstones [12]. Although performing a preventive ERCP every 
year could reduce further CBD stone recurrence in patients who 
have relapsed more than twice after CBD stone removal, it is not 
easy to apply the method in clinical practice [13]. Furthermore, 
it is not always easy to consider ERCP for patients who relapse 
more often than once a year as repeated recurrences can lead 
to serious complications and excessive medical expenses. 
Therefore, another treatment method should be identified. 
Surgical treatment could be an alternative for patients with 
recurring CBD stones [14]. However, surgical treatment is a 
more complex and invasive method than ERCP, and should 
be reserved for selective patients at a high risk of recurrent 
biliary complications, such as those with irreversible severe 
dilatation of the CBD or other patients in whom ERCP fails 
[15]. There are 2 commonly used surgical procedures to treat 
recurrent CBD stones, choledochoduodenostomy (CDS) and 
choledochojejunostomy (CJS), including hepaticojejunostomy. 
The choice is mainly up to the surgeons, considering patient’s 
factors and plans for accessing the CBD and preventing 
recurrence or complications. CDS has been preferred by 
many surgeons due to its anatomical advantages. It is easy 
to perform and permits easy access to ERCP procedures after 
surgery. However, CDS can cause sump syndrome and recurrent 
cholangitis due to reflux of the duodenal contents. CDS cannot 
correct CBD dilation, the biggest risk factor for CBD stone 
recurrence. Therefore, it is not the ultimate treatment in terms 
of CBD stone recurrence [5-7]. Otherwise, CJS is preferable in 
some cases of severe duodenal scarring and high-risk patients 
expected to develop postoperative complications [16,17]. Also, 
when CBD stones recur in patients who underwent CJS, an 
ERCP procedure is difficult due to the altered anatomy, so it 
is inevitably treated with a more invasive method, such as 
percutaneous transhepatic biliary drainage. 
To determine which is ultimately the better surgical 
procedure for rescue therapy for recurrent CBD stones, the 
long-term CBD stone recurrence rate after surgery should be 
compared. The aim of this study was to compare the 2 surgical 




Patients were retrospectively enrolled from 6 academic 
referral centers who underwent surgery due to recurrent CBD 
stones that were not effectively controlled by medical treatment 
and repeated ERCP between January 2006 and March 2015. A 
recurrent CBD stone was defined as a stone found 6 months 
after the complete removal of a CBD stone by ERCP. Patients 
who had a history of stomach surgery or underwent surgery 
for reasons other than recurrent CBD stones or combined 
malignancy were excluded. Patients who underwent surgery 
due to failed ERCP were also excluded. Patients with a surgical 
follow-up period less than 12 months were also excluded. This 
study was approved by the Institutional Review Board of CHA 
Medical Center (No. CHAMC 2020-04-074). As a retrospective 
medical record study, this study was conducted with exemption 
from informed consent.
Data collection
We collected data from chart reviews and medical records, 
including baseline characteristics, CBD stone recurrence rate, 
the interval from the initial CBD stone occurrence to surgery, 
the follow-up period after surgery, the last laboratory results, 
ERCP findings, CT findings before surgery, the types of CBD 
stones, coexisting biliary conditions (cholecystectomy status, 
cholelithiasis, periampullary diverticulum, CBD stricture, etc.), 
the type of surgery, and postoperative complications. The CBD 
diameter was measured by separating the proximal part and the 
distal part on axial CT images and the larger of the 2 values was 
chosen. The diameter immediately distal to the porta hepatis 
was measured for the proximal CBD, while the diameter visible 
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in the head of the pancreas was measured for the distal CBD [18].
The primary outcome of this study was a comparison of 2 
surgical options. The study also investigated differences in the 
clinical results, especially CBD stone recurrence, to explain the 
main reason for the differences.
Statistical analysis
The median and range were used to summarize the data for 
continuous variables and percentages for categorical variables. 
The continuous variables were analyzed using the Mann-
Whitney U-test, and the categorical variables were analyzed 
using Pearson chi-squared test or Fisher exact test. Logistic 
regression analysis was also used to describe the data and 
explain the relationship between the variables. A P-value of 
<0.05 was considered significant. Statistical analyses were 
performed with IBM SPSS Statistics ver. 21.0.0 software (IBM 
Corp., Armonk, NY, USA).
RESULTS
Baseline characteristics and clinical outcomes
Table 1 shows the baseline characteristics and main clinical 
outcomes. Although we analyzed 10 years of data from 6 
hospitals, a total of 27 patients were enrolled in this study. Six 
patients underwent CDS, and 21 patients underwent CJS. There 
were no differences in baseline characteristics and laboratory 
tests results between the 2 groups. Important factors, such 
as the CBD stone recurrence rate before surgery or maximal 
CBD diameter, were not statistically different between the 2 
groups. Also, the type of CBD stones was all brown pigmented 
stones and the coexisting biliary conditions were not different 
between the 2 groups. However, it should be noted that 
periampullary diverticulum and cholecystectomy state, known 
as risk factors for recurrent CBD stones, were frequent in both 
groups. 
The median follow-up period was 290 days (range, 185–1,975 
days) in the CDS group and 1,474 days (range, 190–6,560 days) 
days in the CJS group (P = 0.065). Although the difference was 
not statistically significant, the difference was related to stone 
recurrence after surgical treatment. CBD stones recurred in 4 
patients after CDS (4 of 6, 66.7%) and 3 patients after CJS (3 of 
21, 14.3%) (P = 0.010). The postoperative complications were 
similar and tolerable in both groups. Specifically, although 
intestinal obstruction occurred in 2 patients (2 of 27, 7.4%; 1 in 
each group), all patients completely improved with conservative 
management. There was no mortality in either group.
Fig. 1 shows the most characteristic findings of a patient 
with CBD stone recurrence after CDS operations. A 78-year-
old man underwent laparoscopic cholecystectomy due to 
symptomatic GB stones 9 years before undergoing CDS surgery. 
He was hospitalized multiple times due to acute cholangitis 
caused by multiple recurrent CBD stones, and received 5 
ERCPs over 2 years prior to CDS surgery. Whenever CBD stones 
recur, life-threatening events, such as acute cholangitis, septic 
shock, and acute exacerbation of chronic kidney disease, were 
accompanied. Therefore, CDS surgery was performed as a 
rescue treatment for the recurrent CBD stones. There was no 
recurrence of CBD stones for 20 months after CDS surgery, 
but after that, the patient had 3 recurrences in 10 months. 
Eventually, CJS surgery was performed. The patient was 
Table 1. Baseline characteristics and clinical outcomes
Variable Choledochoduodenostomy group (n = 6) Choledochojejunostomy group (n = 21) P-value
Age (yr) 80.5 (65.0–92.0) 76.0 (51.0–99.0) 0.550
Male sex 5 (83.3) 11 (52.4) 0.029
CBD stone recurrence before surgery (time) 5 (3–8) 5 (4–14) 0.974
Maximal CBD diameter (mm) 17.6 (15.0–26.0) 21.5 (15.0–42.0) 0.240
CBD stricture 2 (33.3) 8 (38.1) >0.999
Periampullary diverticulum 3 (50.0) 14 (66.7) 0.638
Cholecystectomy state 4 (66.7) 15 (71.4) >0.999
Total bilirubin (mg/dL) 1.2 (0.2–5.8) 1.6 (0.3–17.8) 0.569
AST (IU/L) 42 (17–172) 63 (16–517) 0.659
ALT (IU/L) 19 (9–246) 86 (13–653) 0.200
WBC (/μL) 7,800 (7,520–24,510) 9,090 (4,500–22,900) 0.801
CRP (mg/dL) 19.0 (0.44–68.0) 3.2 (0.03–27.93) 0.296
Albumin (g/dL) 4.0 (2.3–4.3) 3.7 (2.3–4.9) 0.801
γ-GTP (U/L) 48 (9–382) 191 (10–739) 0.509
ALP (IU/L) 190 (96–1,706) 266 (45–2,512) 0.705
Follow-up period after surgery (day) 290 (185–1,975) 1,474 (190–6,560) 0.065
CBD stone recurrence after surgery (time) 4 (66.7) 3 (14.3) 0.010
Values are presented as median (range) or number (%). 
CBD, common bile duct.
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Table 2. Univariate analysis of factors associated with common bile duct (CBD) stone recurrence after surgery 
Variable Recurred  patient (n = 7)
Non-recurred  
patient (n = 20)
Odds  
ratio 95% CI P-value
Age (yr) 69.0 (58–82) 80.5 (51–99) 0.942 0.869–1.020 0.138
Male sex 4 (25.0) 12 (75.0) 0.889 0.155–5.084 0.895
CBD stone recurrence before surgery (time) 4 (3–8) 5 (4–14) 0.679 0.430–1.356 0.358
Maximal CBD diameter (mm) 18.8 (15.0–27.0) 21.5 (15.0–42.0) 0.924 0.771–1.107 0.390
Total bilirubin (mg/dL) 1.1 (0.2–15.5) 1.7 (0.3–17.8) 1.003 0.817–1.232 0.974
AST (IU/L) 43 (34–172) 76 (16–517) 0.994 0.981–1.006 0.331
ALT (IU/L) 39.5 (16–246) 86 (9–653) 0.998 0.989–1.007 0.618
WBC (/μL) 9,000 (5,080–13,640) 8,595 (4,500–24,510) 1.000 1.000–1.000 0.362
CRP (mg/dL) 20.41 (0.4–68) 3.17 (0.03–19.0) 1.101 0.968–1.252 0.143
Albumin (g/dL) 4.1 (2.4–4.3) 3.6 (2.3–4.9) 1.567 0.445–5.518 0.484
γ-GTP (U/L) 349 (33–382) 167 (9–739) 0.999 0.994–1.004 0.694
ALP (IU/L) 245 (83–328) 277.5 (45–2,512) 0.997 0.991–1.003 0.255
Choledochoduodenostomy:choledochojejunostomy 4:3 2:18 12.0   1.482–97.179 0.020
Values are presented as median (range), number (%), or number only.
A B C
D E F
Fig. 1. (A) CT findings at the first visit. Heterogeneous material fills in the dilated common bile duct (CBD). (B) Cholangio-
graphy findings by endoscopic retrograde cholangiopancreatography at the first visit. Numerous and various sized round filling 
defects in the dilated CBD. (C) Findings from a cholangiography performed through a nasobiliary drainage tube at the third 
recurrence. Unlike the first attack, larger filling defects are impacted within the dilated CBD. (D) Cholangiography findings at 
the first recurrence of CBD stones after choledochoduodenostomy (CDS). As with previous recurrence findings, large filling 
defects are impacted within the dilated CBD. (E) Endoscopic findings at the third recurrence of CBD stones after CDS. Whitish 
pus is drained from the CDS site. (F) The last CT findings at 48 months after choledochojejunostomy (CJS). Stone recurrence is 
not observed in the remaining proximal CBD and CJS areas.
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undergoing regular outpatient follow-up without recurrence 
of CBD stones for 43 months since the CJS surgery. We believe 
that the inability to correct a CBD dilation up to 26 mm had the 
greatest impact on persistent CBD stone recurrence.
Factors associated with CBD stone recurrence after 
surgery
Table 2 shows the factors associated with CBD stone 
recurrence after surgery. The surgical method was the only 
factor associated with CBD stone recurrence after surgery. CDS 
was more closely associated with stone recurrence after surgery 
than CJS (odds ratio [OR], 12.0; P = 0.020). Importantly, CBD 
diameter, associated with stone recurrence after ERCP, was 
not correlated with stone recurrence after surgical treatment 
(P = 0.390). Coexisting biliary conditions (CBD stricture, 
periampullary diverticulum and cholecystectomy state) were 
excluded from the analysis due to anatomical changes after 
surgery.
DISCUSSION
For endoscopists who perform ERCP, close cooperation with 
surgeons is critical in determining the best treatment of patients 
with pancreato-biliary disease. In general, it is common to have 
a surgical referral to perform a cholecystectomy in patients 
with coexisting gallbladder stones or cholecystitis. In addition, 
if ERCP with stone removal fails, if accompanying biliary 
conditions need to be corrected at the same time, or if CBD 
stones recur too often, a surgical referral may be considered. As 
mentioned earlier, recurrent CBD stones are generally treated 
by an ERCP procedure, which allows patients to return to their 
daily routine without any problems. When the type of recurrent 
CBD stone is a brown pigmented stone and that is not hard 
and consisting of multiple stones, the ERCP procedure is not 
difficult and does not require a high degree of expertise [8-11]. 
However, if CBD stones recur too often in elderly patients, this 
can be accompanied by recurrent cholangitis, hepatic abscess, 
and biliary sepsis, which may be life-threatening. Moreover, 
repeated hospitalizations mean increased medical expenses, 
and this factor should not be ignored. Therefore, to ultimately 
solve this difficult situation, we must consult a surgeon [14,15].
However, ERCP endoscopists usually worry about CBD stone 
recurrence after surgical treatment. Because surgical treatment 
is not an ultimate treatment method to remove all risks of 
CBD stone recurrence, the potential for recurrence cannot be 
ignored. The CDS method has the disadvantage of not usually 
correcting a dilated CBD, but the advantage of being able to 
perform another ERCP procedure when the CBD stone recurs 
is attractive. In contrast, the CJS method can be expected to 
prevent CBD stone recurrence because it corrects dilated CBDs 
to some extent. However, if stones recur, an ERCP procedure 
is generally impossible, putting medical staff in a difficult 
position.
Whether CDS or CJS is the best treatment for CBD stones 
has been discussed for a long time. Long ago, CJS was 
associated with higher operative mortality and procedure-
related complications than CDS. Thus, CDS was recommended 
more often [17]. A multicenter prospective randomized trial 
was performed by a French surgical research group [19]. 
They evaluated age, CBD diameter, operative time, and stone 
recurrence. Although the CBD was markedly dilated (mean CBD 
diameter, 18.22 ± 4.01 mm), the study found no difference in 
long-term outcomes between patients who underwent CDS and 
those who underwent CJS. They recommended and concluded 
that CDS was preferable for CBD stone for 2 reasons. First, CDS 
is technically easier and faster to perform than CJS. Second, 
unlike CJS, CDS permits easy access to further endoscopic 
treatment if necessary. However, the study was designed to 
compare both surgical methods for all CBD stone patients, not 
just for patient with frequent recurrences. A Chinese group 
reported the recurrence of CBD stones after surgical treatment 
in elderly patients [20]. They compared 3 surgical modalities, 
choledocholithotomy with T-tube drainage group, a CDS 
group, and a CJS group. They concluded by recommending 
CDS for elderly patients with primary CBD stones to prevent 
postoperative recurrent CBD stones. However, they enrolled 
only elderly patients over 70 years of age, and older patients are 
more likely to have complications from surgery. The authors 
also mentioned that CJS was a more technically difficult 
method than CDS. 
It is difficult to find research that refutes this statement, but 
clues can be found in the reports of studies on the occlusion 
of plastic stents [21-23]. They suggested that duodeno-biliary 
reflux and bile turbulence plays an important role in stent 
occlusion. Therefore, CBD stone formation might be likely to 
occur in CDS patients with dilated CBDs. Also, since a dilated 
CBD is an important factor in CBD stone formation from bile 
turbulence, the risk of CBD stone recurrence would be corrected 
because CJS or hepaticojejunostomy usually correct dilated 
CBDs to some extent. 
Because of the limited number of studies, we were unable 
to provide an objective answer to the patient’s preoperative 
question, “Doesn’t the CBD stone recur again?” We wanted to 
be convinced that although the CJS method alters the anatomy, 
if it effectively prevents stone recurrence, then a patient rarely 
needs retreatment after surgery.
Our study showed that CJS was a more reasonable surgical 
method to prevent stone recurrence after surgery in patients 
with recurrent CBD stones. Although CJS is technically a more 
difficult surgical procedure, there was no significant difference 
in surgical complications due to refinement in surgeons’ 
techniques and advancements in surgical instruments. Unlike 
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past reports, the postoperative complications were tolerable, 
and there was no mortality in our patients.
As we previously mentioned, comparative studies of the 
prevalence of cholangitis or CBD stones according to the 
method of enterobiliary reconstruction are sparse. There are 
some reports showing no significant difference in the long-term 
outcome of CDS or CJS after choledochal cyst excisions [24,25]. 
However, several studies with a different research objective 
favored CDS because of the lower incidence of duodenogastric 
reflux [26-28]. Although CDS seems more physiological biliary 
drainage, Shimotakahara et al. [29] reported a higher rate 
of endoscopy-proven duodenogastric reflux in a CDS group 
compared to a CJS group (33.3% vs. 0%). Hamada et al. [30] 
also showed that all 17 patients who underwent CDS had 
duodenogastric bile reflux in endoscopic examination, and 14 of 
the 17 patients presented abdominal symptoms, and 7 patients 
underwent CJS conversion surgery for intractable abdominal 
pain. These studies indicate that CJS might be more reasonable 
for biliary-enteric continuity compared to CDS. 
The important points in the baseline characteristics (Table 
1) were that CBD stones recurred an average of 5 times in both 
groups, and the CBD diameter was a median of 17.6 mm (range, 
15–26 mm) in the CDS group, and 21.5 mm (range, 15–42 
mm) in the CJS group. In addition to the above 2 risk factors 
for CBD stone recurrence, periampullary diverticulum was 
present in more than 50% of the patients in both groups, and 
a cholecystectomy state was present in more than two-thirds 
of both groups. The median follow-up period was statistically 
insignificant between the 2 groups, but shorter in the CDS 
group. The difference was related to the stone recurrence 
after surgical treatment. Because CBD stones found within 6 
months after surgery were excluded from the results because 
these patients did not meet the enrollment criteria, that was 
an overlooked part of this study. CBD stones may recur early 
due to postoperative complications after surgery. At the time of 
surgery, a residual CBD stone can be confirmed, so it is difficult 
to determine whether CBD stones found within 6 months are 
residual CBD stones. If this had been further confirmed, the 
results could have been more conclusive.
The main result of this study was that the recurrence of 
CBD stones after surgery was significantly different between 
the 2 groups; 4 of 6 patients (66.7%) in the CDS group vs. 3 of 
21 patients (14.3%) in the CJS group (P = 0.010). Although the 
number of patients in the CDS group was small, the difference 
between the 2 groups was confirmed by a nonparametric 
statistical method. CDS was highly associated with stone 
recurrence than CJS (OR, 12.0; P = 0.020). As mentioned earlier, 
this result can be an important basis for recommending surgery 
to patients. In addition, considering the period of follow-up 
after surgery, the average recurrence rate may be 15% during 
10 years after CJS surgery. In contrast, the average recurrence 
rate may be more than 50% during a relatively shorter period 
after CDS surgery. Therefore, from the perspective of CBD 
stone recurrence, it may be desirable to recommend CJS over 
CDS. Contrary to the results of previous studies, the risk 
factors of recurrent CBD stone before surgery (e.g., dilated CBD, 
periampullary diverticulum, CBD angulation, and CBD stricture, 
etc.) may be corrected after CJS. To accurately prove this, a large-
scale prospective study would be required but might be difficult 
to accomplish due to the quite small number of patients.
The limitations of this study are as follows: (1) This study 
was a retrospective multicenter study and the patients were not 
properly randomized; (2) patients with recurrent CBD stones 
are rarely operated on, so the sample size was quite small. 
The data were collected from 6 academic referral centers for 
10 years, but only 27 patients were enrolled; (3) the number 
of patients in the 2 groups was quite different, and since 
there were only 6 patients in CDS group, there may be a big 
problem in interpreting the results. Therefore, nonparametric 
statistical methods were used for analyzing the results; (4) 
because the surgical treatments were performed at 6 different 
hospitals, differences in surgical skills and equipment could 
have influenced the results of the study; and (5) UDCA was 
administered to all included patients, but whether the patients 
continued to take it was a limitation of the retrospective 
study. Despite these limitations, we believe that our study 
is important because it provides important information to 
clinicians. This study reviewed the results of 2 surgical options 
and provided some important information about related 
problems.
In conclusion, this retrospective multicenter study revealed 
that CDS may be more related to stone recurrence after surgery 
in patients with recurrent CBD stones. Therefore, CJS may be a 
better surgical option than CDS for preventing stone recurrence 
in patients with recurrent CBD stones. We believe that our 
results will serve as a basis for establishing treatment policies 
in that situation. A prospective, randomized, and controlled 
multicenter study would further identify the superiority 
between the 2 surgical options.
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